[
    [
        {
            "time": "2020-08-26",
            "original_text": "复星医药：业绩拐点逐步确认，创新增量提速带动产品结构调整",
            "features": {
                "keywords": [
                    "复星医药",
                    "业绩拐点",
                    "创新增量",
                    "产品结构调整"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：业绩拐点逐步确认，创新增量提速带动产品结构调整",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-26",
            "original_text": "复星医药CEO谈全球首例新冠二次感染：更说明疫苗的必要性",
            "features": {
                "keywords": [
                    "复星医药",
                    "新冠疫苗",
                    "二次感染",
                    "疫苗必要性"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药CEO谈全球首例新冠二次感染：更说明疫苗的必要性",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-08-26",
            "original_text": "复星医药子公司获美洛昔康片《药品生产许可证》",
            "features": {
                "keywords": [
                    "复星医药",
                    "美洛昔康片",
                    "药品生产许可证"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药子公司获美洛昔康片《药品生产许可证》",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-26",
            "original_text": "复星医药总裁吴以芳：国内有望与国外同步，于10月寻求新冠mRNA疫苗上市申请",
            "features": {
                "keywords": [
                    "复星医药",
                    "新冠mRNA疫苗",
                    "上市申请",
                    "国内外同步"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药总裁吴以芳：国内有望与国外同步，于10月寻求新冠mRNA疫苗上市申请",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-26",
            "original_text": "中报业绩披露临近尾声 震荡市中关注行业景气度高的板块",
            "features": {
                "keywords": [
                    "中报业绩",
                    "震荡市",
                    "行业景气度"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中报业绩披露临近尾声 震荡市中关注行业景气度高的板块",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-26",
            "original_text": "A股大幅回调，创业板跌逾2%！但这个板块火了，3只个股20%涨停，资金大幅涌入",
            "features": {
                "keywords": [
                    "A股",
                    "创业板",
                    "回调",
                    "资金流入"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "A股大幅回调，创业板跌逾2%！但这个板块火了，3只个股20%涨停，资金大幅涌入",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-26",
            "original_text": "复星医药半年度实现净利17.15亿元 同比增长13.10%",
            "features": {
                "keywords": [
                    "复星医药",
                    "半年度净利",
                    "同比增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药半年度实现净利17.15亿元 同比增长13.10%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]